FDA clears Teleflex’s latest midline catheter for U.S. market

The FDA granted Teleflex ($TFX) 510(k) clearance to begin marketing its Arrow Midline with Chlorag+ard technology for use in the U.S. market.

The device is an antithrombogenic and antimicrobial peripheral venous catheter that minimizes common midline catheter complications such as catheter intraluminal occlusion, thrombus accumulation and microbial colonization on the catheter surface for at least 30 days, the company said.

Additionally, the device allows caregivers to more easily protect the catheter from potential costly complications.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Teleflex's Arrow unit makes a variety of the catheters under the brand names of UltraFlex, NarrowFlex and RediGuard.

“Clinicians are faced with a multitude of vascular access challenges,” Jay White, president and GM of Teleflex’s Vascular Access Division, said in a statement. “Development of new technology to ensure the patient receives the safest, most effective IV therapy possible should drive all medical device manufacturers.”

Earlier this year, the Wayne, PA-based company issued a global Class I corrective recall of more than 47,000 Arrow International intra-aortic balloon catheter kits and percutaneous insertion kits after it reported the separation of the devices' sheath body from the sheath hub had resulted in six serious injuries and one death.

Suggested Articles

The FDA warned healthcare providers about cybersecurity vulnerabilities within certain clinical information systems made by GE Healthcare.

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

As public fascination with at-home DNA tests begins to wane, 23andMe announced that it will lay off about 100 of its staff, according to CNBC.